Skip to main content

Horizant FDA Approval History

FDA Approved: Yes (First approved April 6, 2011)
Brand name: Horizant
Generic name: gabapentin enacarbil
Dosage form: Extended Release Tablets
Previous Name: Solzira
Company: Azurity Pharmaceuticals, Inc.
Treatment for: Restless Legs Syndrome, Postherpetic Neuralgia

Horizant (gabapentin enacarbil) is a gabapentin prodrug indicated for the once-daily treatment of restless legs syndrome and postherpetic neuralgia.

Development timeline for Horizant

DateArticle
Jun  7, 2012Approval GSK and XenoPort Receive FDA Approval for Horizant for Postherpetic Neuralgia
Apr  6, 2011Approval GlaxoSmithKline and XenoPort Receive FDA Approval for Horizant
Nov  8, 2010GlaxoSmithKline and XenoPort Respond to FDA on Horizant for RLS
Feb 19, 2010Depomed Comments on DM-1796 Pre-NDA Meeting and Horizant Complete Response Letter
Feb 18, 2010GlaxoSmithKline and XenoPort Receive FDA Complete Response Letter for Horizant (GSK1838262/XP13512) for RLS
Feb 10, 2010XenoPort Announces Extension of the Horizant PDUFA Date to February 11, 2010
Feb  4, 2010XenoPort Announces Horizant as Brand Name for XP13512
Mar 16, 2009XenoPort to Receive $23 Million in Milestone Payments Associated With FDA Acceptance of Solzira NDA
Jan  9, 2009GSK and XenoPort Resubmit New Drug Application for Solzira in Restless Legs Syndrome
Nov 10, 2008GSK and XenoPort Announce Plans to Withdraw and Resubmit New Drug Application Requesting Approval of Solzira for Restless Legs Syndrome
Sep 16, 2008GSK and XenoPort Announce Submission of NDA Requesting FDA Approval of Solzira for Restless Legs Syndrome

See also

Horizant (gabapentin enacarbil) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer